Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463691 | 0.96 | KCNH2 (0.49) | SIGMAR1KCNH2KCNJ1KDM4ENPC1 | |
| SCHEMBL18371471 | 0.85 | ALPL (0.40) | KMT2A | |
| SCHEMBL408760 | 0.85 | KMT2A (0.44) | SIGMAR1ALDH1A1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL18021181 | 0.84 | SIGMAR1 (0.41) | SIGMAR1KCNH2KCNJ1ALDH1A1KMT2A | |
| SCHEMBL13013957 | 0.82 | LMNA (0.42) | SIGMAR1ALDH1A1KMT2ASMN1; SMN2HRH3 | |
| SCHEMBL18021195 | 0.81 | SIGMAR1 (0.45) | SIGMAR1KCNH2KCNJ1ALDH1A1KMT2A | |
| SCHEMBL463093 | 0.80 | ALDH1A1 (0.44) | SIGMAR1KCNH2ALDH1A1KMT2AKDM4E | |
| SCHEMBL3773844 | 0.79 | SIGMAR1 (0.39) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL18021164 | 0.79 | SIGMAR1 (0.44) | SIGMAR1KCNH2KCNJ1ALDH1A1KMT2A | |
| SCHEMBL18021169 | 0.79 | SIGMAR1 (0.41) | SIGMAR1KCNH2KCNJ1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | CHONG, HYUN-SOON, PHD | 2017-01-12 | — | — | US | disclosed |
| US-9115094-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) (US) | 2015-08-25 | — | — | US | disclosed |
| US-8986650-B2 | Complex folate-NOTA-Ga68 | GUERBET (FR) | 2015-03-24 | — | — | US | disclosed |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | GUERBET (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | SIGMAR1 1437/4885KCNH2 1860/4885KCNJ1 4043/4885 |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | AZI2, ABL1, DHPS | SIGMAR1 3169/4885KCNH2 710/4885KCNJ1 296/4885 |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | FOLR1, FOLR2, DHFR | SIGMAR1 1734/4885KCNH2 4549/4885KCNJ1 4800/4885 |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, PKD1 | SIGMAR1 870/4885KCNH2 3525/4885KCNJ1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.